SELECTA BIOSCIENCES, INC.

Biotech · Acquired

Biodegradable nanoparticles (PLGA-based) delivering antigens and immunosuppressive drugs to induce antigen-specific immune tolerance

Grants
$225K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
24
0 granted · 24 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Nanoparticles for Immune Tolerance to FVIII$225,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2931Annias Immunotherapeutics, Inc.——
2932INDUSTRIAL SONOMECHANICS, LLC——
2933ADEPTHERA, LLC——
2934SELECTA BIOSCIENCES, INC.——
2935QUANTUMBIO INC——
2936CBS THERAPEUTICS, INC.——
2937Dayra Therapeutics——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 24
  • Methods Of Administering Immunosuppressants Having A Specified Pharmacodynamic Effective Life And Therapeutic Macromolecules For The Induction Of Immune Toleranceapplication
  • Tolerogenic Synthetic Nanocarriers For Allergy Therapyapplication
  • Tolerogenic Synthetic Nanocarriersapplication
  • Viral Vector Dosing Protocolsapplication
  • High Affinity IL-2 Receptor Agonists And Immunosuppressants To Enhance Immune Toleranceapplication
  • Synthetic Nanocarriers Comprising An Immunosuppressant In Combination With High Affinity IL-2 Receptor Agonists And Anti-igm Agentsapplication
  • Methods And Compositions For Attenuating Anti-viral Transfer Vector Immune Responsesapplication
  • Immunosuppressants In Combination With Anti-igm Agents And Related Dosingapplication
  • Immunosuppressant In Combination With High Affinity IL-2 Receptor Agonists And Related Dosingapplication
  • Tolerogenic Synthetic Nanocarriers To Reduce Immune Responses To Therapeutic Proteinsapplication
  • Immunosuppressant In Combination With High Affinity IL-2 Receptor Agonists For Diabetesapplication
  • Modulation Of High Affinity IL-2 Receptor Agonist Effects With Immunosuppressantapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.